REG - J.P. Morgan Sec PLC GlaxoSK Capital PLC - Stabilisation Notice

GSKAnnouncement

05/05/2020 09:10

RNS Number : 9416L
  
J.P. Morgan Securities PLC.
  
05 May 2020
  
 

05 May 20   
Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.
GlaxoSmithKline Capital plc
Post-stabilisation Period Announcement
Further to the pre-stabilisation period announcement 04 May 20, J.P. Morgan Securities plc, (contact: Emma Lovett 0207 134 2468) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.



Issuer:


GlaxoSmithKline Capital plc




Guarantor (if any):


N/A




Aggregate nominal amount:


GBP Long 8Y - GBP 750mm
GBP 15Y - GBP 750mm
EUR 3Y - EUR 750mm




Description:


GBP Long 8Y FXD Senior Unsecured Notes
GBP 15Y FXD Senior Unsecured Notes
EUR 3yr FXD Senior Unsecured Notes
Listing: London Stock Exchange




Stabilisation Manager(s):


J.P. Morgan Cazenove (Stabilisation coordinator)
Barclays (Stabilisation Manager(s))
GSI (Stabilisation Manager(s))
HSBC (Stabilisation Manager(s))
 




Offer price:


99.954



 
This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction
This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
STAEAXSSEESEEEA